Aldeyra Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M |
| Interest expense | $1.9M | $1.9M | $2.1M | $1.7M | $1.7M |
| Pretax income | — | — | — | — | -$57.8M |
| Income tax expense | $0 | $1,000 | $0 | $0 | $0 |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M |
| Balance Sheet | |||||
| Cash and equivalents | $70.0M | $54.5M | — | $144.4M | $229.8M |
| Current assets | $71.8M | $104.1M | $147.8M | $181.0M | $232.8M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M |
| Current liabilities | $27.8M | $18.6M | $22.3M | $15.4M | $11.8M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M |
| Stockholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M |
| Depreciation and amortization | $251,993 | $249,623 | $262,780 | $258,707 | $264,180 |
| Stock-based compensation | $6.1M | $8.0M | $5.8M | $8.3M | $7.1M |
| Capital expenditure | — | — | $0 | $16,317 | $7,806 |
| Free cash flow | — | — | -$30.3M | -$56.7M | -$42.6M |
Shares outstanding 60.3M · Free float 78.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.